Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Neoplasms × Depsipeptides × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Small Cell Lung Carcinoma 2 Mesothelioma, Malignant 2 Carcinoma, Non-Small-Cell Lung 2 Oligodendroglioma 1 Neoplasms 1 Mesothelioma 1 Lymphoma, T-Cell 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell 1 Lung Neoplasms 1 Hodgkin Disease 1 Gliosarcoma 1 Glioblastoma 1 Esophageal Neoplasms 1 Carcinoma, Small Cell 1 Burkitt Lymphoma 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Cyclophosphamide 13 Bevacizumab 9 Interleukin-2 8 aldesleukin 7 fludarabine 6 fludarabine phosphate 5 Gemcitabine 5 Filgrastim 5 sargramostim 4 Vincristine 4 Trastuzumab 4 Thalidomide 4 Radiotherapy 4 Prednisone 4 Paclitaxel 4 Leucovorin 4 Bortezomib 4 Biopsy 4 veliparib 3 vandetanib 3 tariquidar 3 pazopanib 3 montanide ISA 51 3 Topotecan 3 Sorafenib 3 Sirolimus 3 Oxaliplatin 3 Melphalan 3 MART-1 Antigen 3 Fluorouracil 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡